• Biogen expects Q2 2026 results to include about $164 million of acquired IPR&D, upfront, milestone expense, cutting GAAP and non-GAAP EPS by about $0.95.
• Q3 2026 charge forecast at about $290 million-$320 million tied to potential milestones, transactions not yet closed; EPS impact seen at about $1.75-$1.95.
• Items reflect collaboration and license deals, including upfront or milestone payments, equity premiums, asset acquisitions of acquired IPR&D.
• June 30, 2026 quarter results not finalized; estimates subject to closing procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000875045-26-000068), on July 01, 2026, and is solely responsible for the information contained therein.